This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Donnelly School of Biomedical Research | |
|---|---|
| Name | Donnelly School of Biomedical Research |
| Established | 1998 |
| Type | Research institute |
| Location | Chicago, Illinois |
| Director | Maria E. Alvarez |
| Affiliations | University of Chicago; Northwestern University |
Donnelly School of Biomedical Research is a multidisciplinary biomedical research institute located in Chicago, Illinois, focused on translational and basic science research in molecular biology, neuroscience, immunology, and regenerative medicine. Founded in the late 1990s, the school has developed collaborative programs in partnership with major universities and healthcare systems and hosts graduate and postdoctoral training programs. Researchers at the school have contributed to advances in gene editing, stem cell biology, neurodegenerative disease mechanisms, and immunotherapy.
The Donnelly School of Biomedical Research was founded in 1998 with philanthropic support from the Donnelly Foundation and leadership drawn from academia and industry including faculty with prior appointments at Harvard Medical School, Massachusetts Institute of Technology, Stanford University School of Medicine, University of California, San Francisco, and Johns Hopkins University. Early collaborations included projects with Mayo Clinic, Cleveland Clinic, Memorial Sloan Kettering Cancer Center, Salk Institute, and Cold Spring Harbor Laboratory, enabling rapid expansion of molecular oncology, developmental biology, and neurobiology programs. Across the 2000s the school recruited investigators formerly affiliated with Rockefeller University, Columbia University Irving Medical Center, University of Pennsylvania Perelman School of Medicine, Yale School of Medicine, and University of Michigan Medical School, and established core facilities inspired by models from Broad Institute and Howard Hughes Medical Institute. Major milestones included acquisition of dedicated clinical collaborations with Northwestern Memorial Hospital and affiliation agreements with Rush University Medical Center and Lurie Children’s Hospital of Chicago.
The school's mission emphasizes translational discovery bridging basic science and clinical application, aligning research priorities with initiatives at National Institutes of Health, Wellcome Trust, Howard Hughes Medical Institute, European Research Council, and private foundations such as Gordon and Betty Moore Foundation and Simons Foundation. Primary research foci include molecular genetics, epigenetics, structural biology, immuno-oncology, neurodegeneration, and regenerative medicine, with specific programs addressing disorders studied at Broad Institute, Scripps Research, Whitehead Institute, and Allen Institute for Brain Science. The mission statement references partnerships modeled after collaborations among Dana-Farber Cancer Institute, Fred Hutchinson Cancer Center, Vanderbilt University Medical Center, and University of California, San Diego.
Graduate and postdoctoral programs at the school incorporate curricula comparable to those at University of Chicago, Northwestern University Feinberg School of Medicine, Columbia University, and University of Pennsylvania. Trainees participate in rotations and coursework with faculty who have held appointments at Princeton University, Brown University, Duke University School of Medicine, Icahn School of Medicine at Mount Sinai, and Baylor College of Medicine. Professional development emphasizes grant writing, clinical translation, and entrepreneurship in partnership with industry collaborators such as Pfizer, Roche, Novartis, Amgen, and Merck & Co., and with technology transfer guidance drawn from Stanford Office of Technology Licensing and MIT Technology Licensing Office. Visiting scholar programs have hosted researchers from Imperial College London, Karolinska Institutet, Max Planck Society, and University of Toronto.
Core facilities supporting research include high-throughput sequencing, cryo-electron microscopy, high-field nuclear magnetic resonance, single-cell genomics, advanced imaging, and bioinformatics modeled on platforms found at Cold Spring Harbor Laboratory, European Molecular Biology Laboratory, Lawrence Berkeley National Laboratory, and Argonne National Laboratory. Specialized centers encompass a Center for Neurodegenerative Disease Research influenced by programs at Scripps Research and Institute Pasteur, an Immuno-Oncology Center with translational pipelines analogous to Memorial Sloan Kettering Cancer Center and City of Hope, and a Regenerative Medicine Center collaborating with networks like California Institute for Regenerative Medicine and Cellular Tissue Engineering Consortium.
Researchers at the school have published influential work on CRISPR-based genome editing techniques building on discoveries from University of California, Berkeley, Massachusetts Institute of Technology, and Harvard University, advances in induced pluripotent stem cell differentiation related to studies at Kyoto University and Gladstone Institutes, and mechanistic insights into Alzheimer’s and Parkinson’s disease pathways paralleling research at Columbia University and Mount Sinai. The school contributed to translational immunotherapy strategies that echo clinical developments from Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center, and co-developed imaging technologies consistent with innovations from National Institutes of Health intramural programs and Howard Hughes Medical Institute investigators. Collaborative publications have appeared alongside authors from Broad Institute, Salk Institute, Rockefeller University, Cold Spring Harbor Laboratory, and Wellcome Sanger Institute.
Formal affiliations include partnership agreements with University of Chicago, Northwestern University, Rush University Medical Center, Lurie Children’s Hospital of Chicago, and multi-institutional consortia such as those involving National Cancer Institute and National Institute of Neurological Disorders and Stroke. Industry partnerships have been established with Genentech, Gilead Sciences, Biogen, AstraZeneca, and biotechnology firms modeled after Moderna and Regeneron Pharmaceuticals. International collaborations extend to Karolinska Institutet, Max Planck Society, CNRS, EMBL, and University of Oxford.
Governance is overseen by a Board of Trustees with members drawn from academia, philanthropy, and industry, including leaders with prior roles at Bill & Melinda Gates Foundation, Rockefeller Foundation, Ford Foundation, and Robert Wood Johnson Foundation. Research funding derives from competitive grants from National Institutes of Health, National Science Foundation, Wellcome Trust, foundation awards from Simons Foundation and Gordon and Betty Moore Foundation, philanthropy from donors similar to Donnelly Foundation and Carnegie Corporation, and sponsored research agreements with pharmaceutical partners such as Pfizer and Roche. Financial oversight follows models practiced at Imperial College London and University College London.